Match each mood stabilizer or second-generation antipsychotic used in the management of bipolar disorder with its most characteristic adverse effect profile, baseline monitoring requirement, or presentation of toxicity.
- LithiumToxicity is characterized by coarse tremors, ataxia, and delirium; clearance is significantly reduced by concurrent NSAID or thiazide diuretic use.
- ValproateAssociated with dose-dependent thrombocytopenia, hyperammonemic encephalopathy, and requires baseline liver function tests.
- LamotrigineRequires slow up-titration over several weeks to minimize the risk of life-threatening dermatologic reactions; effective for bipolar depression.
- QuetiapineCarries a high risk for metabolic syndrome, requiring baseline and routine monitoring of fasting lipids, glucose, and weight.
Answer
Lithium corresponds to NSAID interactions and coarse tremors. Valproate corresponds to hepatotoxicity and thrombocytopenia. Lamotrigine corresponds to slow titration to avoid severe rash. Quetiapine corresponds to metabolic syndrome monitoring.
Matching mood stabilizers to their profiles tests essential pharmacologic knowledge. Lithium causes neurologic toxicity exacerbated by renally active drugs. Valproate is hepatotoxic and suppresses platelets. Lamotrigine requires slow titration due to severe rash risk. Quetiapine commonly induces metabolic derangements.
Step-by-Step Solution
Key Concept
Pharmacologic management of bipolar disorder: adverse effects and monitoring
Estimated Time:1m 30s